Interestingly, PTEN loss conferred resistance against EGFR inhibitors in colorectal and lung cancer [62, 63], against herceptin in breast cancer [64] or even BRAF inhibitors in melanoma [65]. This evidence concerns the gene EGFR and lung cancer.